I have always been fascinated with the diagnostic industry as I have worked on many projects related to it....Bayer as a company is the name I remember from my childhood days as we used to use a lot of Baygon spray at our home in tropical islands of Andaman. After joining the KPO industry in 2007, I have been keeping a track of Bayer in general with regards to its Diagnostic portfolio, Bayer used to sell its blood glucose meters along with J&J and Roche who are also one of the major players in the segment of continuous and other blood sugar diagnosis systems.....but yesterday there was a news that it is going to discontinue any advances in the current portfolio and has shifted its focus on Companion diagnostic for oncology by forming an alliance with Qiagen....this year we had two more major events in this companion diagnostic segment, Roche has released its press release for its interest in companion diagnostic for Breast cancer and further BMS went ahead for alliance with Life tech for companion diagnostics in Oncology......Both BMS and Bayer are moving into the space but what we have to look for if Roche will only restrict itself with companion diagnostics for Breast cancer or it will further expand into other Oncology indications???
Roche as a science driven company, has a good hold in both blood sugar diagnosis system and now will eventually try to have a monopoly in companion diagnostics......what we have to see if J&J joins the race by partnering with Agilent or will continue with its own program which it started in 2011 or some other big fish going to join the race pretty soon?
Roche as a science driven company, has a good hold in both blood sugar diagnosis system and now will eventually try to have a monopoly in companion diagnostics......what we have to see if J&J joins the race by partnering with Agilent or will continue with its own program which it started in 2011 or some other big fish going to join the race pretty soon?
No comments:
Post a Comment